헌팅턴병 치료 시장 규모, 점유율, 동향 분석 리포트 : 치료별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Huntington´s Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Treatment, Disease-Modifying Therapies), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,641,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,094,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,998,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

헌팅턴병 치료 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 헌팅턴병 치료 시장 규모는 2025-2030년에 23.8%의 CAGR을 기록하며, 2030년까지 18억 7,120만 달러에 달할 전망입니다. 이러한 성장은 신제품 개발을 위한 높은 R&D 투자, 공동 연구, 유럽과 미국에서의 높은 HD 부담에 기인합니다. 헌팅턴병은 희귀한 유전성 신경 퇴행성 질환으로 여러 세대에 걸쳐 발병하며, 30세에서 50세 사이에 발병하여 직장이나 가족을 돌보는 능력이 손상되고 결국 일상적인 업무를 수행할 수 없게 됩니다.

유병률은 지역에 따라 10배 이상의 차이가 있으며, 이는 사례 파악 및 진단 기준의 편차와 관련이 있을 것으로 추정됩니다. 유병률은 지역에 따라 10배 이상의 차이가 있으며, 이는 사례 확인 및 진단 기준의 차이와 관련이 있을 수 있습니다. 그 결과, 일반 인구에서 반복성 비대의 유병률은 예상보다 높을 수 있습니다. 아시아에서는 일관되게 낮은 유병률을 보이며, 북미와 호주에서는 높은 유병률을 보입니다.

뉴로크라인 바이오사이언스, 아제반 파마슈티컬스(Azevan Pharmaceuticals) 등 주요 기업이 HD 치료제 연구개발에 집중하고 있으며, 아제반 파마슈티컬스(Azevan Pharmaceuticals)는 SRX246을 헌팅턴병의 정신신경증상을 치료하는 실험약으로 개발하고 있습니다. SRX246은 뇌내 바소프레신1a(V1a) 수용체를 억제하여 효과를 발휘하는 약물입니다. 신경계에서 V1a 수용체는 주요 바소프레신 수용체이며, SRX246은 V1a 수용체를 억제함으로써 바소프레신이 수용체에 결합하는 것을 제한하여 헌팅턴병 환자에서 나타나는 과민하고 공격적인 행동을 유발합니다.

그러나 현재 승인된 약물은 대증요법이나 완화 치료일 뿐, 질병의 근본적인 원인을 치료하는 것은 아닙니다. 약물 치료는 증상의 심각성을 감소시킬 수 있지만, 졸음, 보행 장애, 연하 장애, 무기력 등의 부작용을 동반하는 경우가 많아 환자의 삶의 질에 심각한 영향을 미칠 수 있습니다. 이 질환에 대한 치료법이 확립되지 않았기 때문에 이들 환자의 건강 관련 삶의 질(HRQOL)이 어떻게 영향을 받는지 평가하는 것은 매우 중요합니다. 초기부터 중기 HD 환자들은 인지기능 평가와 상담 등 다학제적 의료서비스가 필요합니다.

2020년 9월, Vaccinex Inc.의 페피네맙(pepinemab)의 임상 2상 시험은 초기 발현 HD 환자 및 전구기 HD 환자를 대상으로 한 SIGNAL 시험에서 두 가지 공동 주요 평가변수인 인지기능 평가지표와 임상적 세계 인지기능 변화 평가지표(CGIC)를 충족하지 못했습니다. SIGNAL 임상에서 두 가지 공동 주요 평가변수(Huntington's disease cognitive function assessment battery와 CGIC(Clinical Global Impression of Change)의 두 가지 인지기능 평가변수)는 초기 증상 환자군에서 통계적 유의성을 달성하지 못했습니다. 에서 통계적 유의성을 달성하지 못했습니다.

헌팅턴병 치료 시장 보고서 하이라이트

• 증상 치료 분야는 제품의 가용성과 특허 보호로 인해 2024년 가장 큰 매출 점유율을 차지했습니다. SAGE-718과 Cellavita-HD의 진입으로 인해 질병 변형 치료는 예측 기간 중 가장 빠르게 성장할 것으로 예측됩니다.
• 각 업체들은 현재 돌연변이 단백질을 표적으로 삼는 것이 아니라, 뇌에 직접 주사하여 돌연변이 HTT 단백질의 형성을 직접 억제하는 치료제 개발에 집중하고 있습니다.
• 개발 초기 단계에 있는 신규 표적 치료제에는 Cellavita와 Azidus Brazil의 Cellavita HD(줄기세포치료제), Sangamo Therapeutics의 mHTT ZFP(징크 핑거 단백질), UniQure의 AMT-130(유전자치료제) 등이 있습니다.
• 북미는 2024년 가장 높은 매출 점유율을 차지했으며, 미국과 캐나다는 상환 시설이 잘 갖추어져 있고 HD에 대한 부담이 크기 때문에 예측 기간 중에도 시장을 지배할 것으로 보입니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 시장의 변수, 동향, 범위

• 시장 계통 전망
  • 모시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 헌팅턴병 치료 시장 분석 툴
  • 업계 분석 - Porter의 산업 분석
  • PESTEL 분석
  • 가격 분석
  • 파이프라인 분석

제4장 헌팅턴병 치료 시장 : 치료 추정·동향 분석

• 세계의 헌팅턴병 치료 시장 : 치료 대시보드
• 세계의 헌팅턴병 치료 시장 : 치료 변동 분석
• 헌팅턴병 치료 시장(치료, 매출별)
• 치료
• 질환 조절 요법

제5장 헌팅턴병 치료 시장 : 유통 채널 추정·동향 분석

• 헌팅턴병 치료 세계 시장 : 유통 채널 대시보드
• 헌팅턴병 치료 세계 시장 : 유통 채널 변동 분석
• 헌팅턴병 치료 시장(유통 채널별, 매출별)
• 병원 약국
• 소매 약국
• 온라인 약국

제6장 헌팅턴병 치료 시장 : 치료, 용도, 유통 채널별 지역 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 주요 시장 참여 기업에 의한 최근 동향과 영향 분석
• 기업/경쟁 분류
• 벤더 구도
  • 주요 판매 대리점 및 채널 파트너 리스트
  • Key customers
  • Key company market share analysis, 2024년
  • H. Lundbeck A/S.
  • Teva Pharmaceutical Industries Ltd.
  • Bausch Health Companies Inc.
  • Hetero
  • Lupin
  • Hikma Pharmaceuticals PLC
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • uniQure NV.
  • Latus Bio

KSA

영문 목차

영문목차

Huntington's Disease Treatment Market Growth & Trends:

The global huntington's disease treatment market size is expected to reach USD 1,871.2 million by 2030, registering a CAGR of 23.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is due to high R&D investments for new product development, research collaboration, and the high HD burden in western countries. Huntington's disease is a rare inherited neurodegenerative disease that affects several generations. It affects people between the ages of 30 and 50, impairing their capacity to work, care for their families, and, eventually, complete daily tasks.

The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. As a result, the prevalence of enlarged repetitions in the general population may be greater than expected. The Asian population has consistently had a lower prevalence, while Europe, North America, and Australia have a higher prevalence.

The key players, such as Neurocrine Biosciences, Inc. and Azevan Pharmaceuticals, Inc., are focusing on research and development of symptomatic therapies for HD. Azevan Pharmaceuticals is developing SRX246 as an experimental drug to treat neuropsychiatric symptoms in Huntington's disease. SRX246 is a drug that works by blocking the vasopressin 1a (V1a) receptor in the brain. In the neurological system, V1a receptor is the major vasopressin receptor. SRX246 works by inhibiting the V1a receptor, restricting vasopressin from attaching to the receptor, and generating irritable and aggressive behavior, which is seen in Huntington's disease patients.

However, currently approved drugs provide symptomatic and palliative care and do not target the underlying cause of the disease. While medications can decrease the severity of symptoms, they are often associated with adverse effects such as somnolence, gait issues, dysphagia, and apathy, which can have serious impacts on a patient's quality of life. Given the lack of a cure for the disease, it is critical to evaluate how Health-related Quality of Life (HRQOL) is affected in these patients. HD patients in early to middle stages of the disease need coordinated multidisciplinary healthcare services, including assessment of cognitive function and counseling.

Drug development for HD has faced significant obstacles as several therapies have failed to demonstrate efficacy or were associated with significant toxicity. Vaccinex Inc.'s phase II trial of Pepinemab failed to satisfy pre-specified co-primary endpoints in patients with early manifest and prodromal HD, in September 2020. The two co-primary endpoints-a family of two cognitive evaluations from the Huntington's disease Cognitive Assessment Battery and Clinical Global Impression of Change (CGIC)-did not attain statistical significance in the early manifestation population in the SIGNAL study.

Huntington's Disease Treatment Market Report Highlights:

• The symptomatic treatment segment accounted for the largest revenue share in 2024 owing to the product availability and patent protection. Disease-modifying therapies is anticipated to be the fastest-growing segment over the forecast years due to the entry of SAGE-718, and Cellavita-HD
• Companies are now focusing on the development of treatments that can be injected directly into the brain to directly inhibit the formation of mutant HTT protein, instead of targeting the mutant protein
• Drugs with novel targets in early-phase development include Cellavita and Azidus Brazil's Cellavita HD (stem cell therapy), Sangamo Therapeutics, Inc. mHTT ZFP (zinc finger protein), and UniQure's AMT-130 (gene therapy)
• North America held the highest revenue share in 2024 and is expected to dominate the market over the forecast period due to better reimbursement facilities and the high burden of HD in the U.S. and Canada

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. Distribution Channel
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment and Distribution Channel Outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising anti-aging burden
    • 3.2.1.2. Advancements in drug development
    • 3.2.1.3. Growing awareness about anti-aging treatment
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of development
    • 3.2.2.2. Regulatory challenges for new drug approvals
• 3.3. Huntington's Disease Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis
  • 3.3.4. Pipeline Analysis
    • 3.3.4.1. Phase 1
    • 3.3.4.2. Phase 2
    • 3.3.4.3. Phase 2

Chapter 4. Huntington's Disease Treatment Market: Treatment Estimates & Trend Analysis

• 4.1. Global Huntington's Disease Treatment Market: Treatment Dashboard
• 4.2. Global Huntington's Disease Treatment Market: Treatment Movement Analysis
• 4.3. Global Huntington's Disease Treatment Market by Treatment, Revenue
• 4.4. Symptomatic Treatment
  • 4.4.1. Symptomatic Treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.5. Disease-modifying Therapies
  • 4.5.1. Disease-modifying Therapies market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Huntington's Disease Treatment Market: Distribution Channel Estimates & Trend Analysis

• 5.1. Global Huntington's Disease Treatment Market: Distribution Channel Dashboard
• 5.2. Global Huntington's Disease Treatment Market: Distribution Channel Movement Analysis
• 5.3. Global Huntington's Disease Treatment Market by Distribution Channel, Revenue
• 5.4. Hospital Pharmacy
  • 5.4.1. Hospital Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Retail Pharmacy
  • 5.5.1. Retail Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.6. Online Pharmacy
  • 5.6.1. Online Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Huntington's Disease Treatment Market: Regional Estimates & Trend Analysis by Treatment, Application, and Distribution Channel

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2024
  • 7.3.4. H. Lundbeck A/S.
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Teva Pharmaceutical Industries Ltd.
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Treatment benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Bausch Health Companies Inc.
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Hetero
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Lupin
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Hikma Pharmaceuticals PLC
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Dr. Reddy's Laboratories Ltd.
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Sun Pharmaceutical Industries Ltd.
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Novartis AG
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. uniQure NV.
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Product benchmarking
    • 7.3.13.4. Strategic initiatives
  • 7.3.14. Latus Bio
    • 7.3.14.1. Company overview
    • 7.3.14.2. Financial performance
    • 7.3.14.3. Product benchmarking
    • 7.3.14.4. Strategic initiatives

관련자료